KRAS and cancer: In vivo tumorigenesis experiments with 15 cancer cell lines in a variety of genetic backgrounds revealed striking sensitivity of tumors driven by oncogenic KRAS, but not other Ras isoforms, to loss of these vesicular transport proteins.